199results about "Phosphorous compound active ingredients" patented technology

This present disclosure provides reliable methods and apparatus for delivering microdroplets containing an active pharmaceutical ingredient (API) to underlying substrates. A control system is provided to ensure that the API dosage is both accurate and repeatable.

Provided are novel formulations of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate as described below and uses thereof.

Disclosed herein are compounds, pharmaceutical compositions, and methods for treating RIPK1-mediated diseases, such as neurodegenerative disorders, inflammatory disorders, and cancer, that inhibit RIPK1.

The present disclosure relates to compounds of formula (I), which are formylpeptide 2 (FPR2) receptor agonists and / or formylpeptide 1 (FPR1) receptor agonists. The disclosure also provides compositions and methods using the compounds to treat, for example, atherosclerosis, heart failure, chronic obstructive pulmonary disease (COPD), and related diseases. TIFF2023533037000263.tif35138

The present disclosure relates to a technique for synthesizing with high yield a novel compound targeting mitochondria through a simple process, and the novel compound synthesized thereby. The novel compound targeting mitochondria of the present disclosure can be synthesized with high yield through a simple process and the compound thus prepared and nanoparticles containing same exhibit the therapeutic effects of targeting mitochondria, inhibiting gastric cancer, and treating inflammatory bowel disease, and systemic sclerosis and thus can be utilized for mitochondrial targeting applications, as anticancer compositions, or as therapeutic compositions for immune diseases.

The present invention relates to an anti-tumor use of a phosphorus compound. Specifically, the present invention provides a use of a compound of formula (I), an optical isomer thereof, a racemate thereof, a solvate thereof, a pharmaceutically acceptable salt thereof or a deuterated compound thereof in preparation of a composition or a preparation, wherein the composition or the preparation is used for preventing and / or treating tumors. The compound of the present invention exhibits excellent precise therapeutic efficacy against tumors characterized by high expression of kinase B.

The disclosure relates to certain compounds that can be consumed by a human subject to modulate the levels of plasmalogens in the subject to provide improved health outcomes. The disclosure further relates to the formulation of said compounds, compositions comprising at least one compound, and uses thereof.

The present invention relates to compounds containing a phosphonium salt group, as well as related salts, double salts, solvates, and pharmaceutical compositions. The present invention also relates to the use of such compounds and compositions in the treatment and prevention of medical disorders and diseases, particularly in the treatment and prevention of cancer.

The invention belongs to the technical field of agricultural biology, and particularly relates to application of an endoplasmic reticulum protein antioxidant (reducing agent) in prevention and treatment of bombyx mori nuclear polyhedrosis virus. A screening test finds that the related endoplasmic reticulum protein antioxidants beta-mercaptoethanol (BME), dithiothreitol (DTT) and / or tris (2-carboxyethyl) phosphine (TCEP) have the effect of inhibiting the bombyx mori nuclear polyhedrosis virus (BmNPV), and the antioxidants interfere the replication and proliferation of the virus by destroying disulfide bonds in key proteins of the BmNPV, so that the bombyx mori nuclear polyhedrosis virus can be inhibited. The stability and activity of virions are directly influenced, so that the infection of the viruses on the silkworms is inhibited, a brand new thought is provided for the development of antiviral drugs of the silkworms, and the application value is good.

Compounds, compositions, and methods for inhibiting ENPP1 are provided. Embodiments of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell-impermeable. The ENPP1 inhibitor compound can act extracellularly and block the degradation of cGAMP. Similarly, pharmaceutical compositions and methods for treating cancer are provided. Embodiments of the method include administering a therapeutically effective amount of an ENPP1 inhibitor to a subject to treat the cancer in the subject. In certain cases, the cancer is a solid tumor cancer. Similarly, methods are provided in which radiation therapy is administered to a subject in conjunction with administering an ENPP1 inhibitor to the subject. In the subject methods, radiation therapy can be administered at a dosage and / or frequency effective to reduce radiation damage to the subject while still eliciting an immune response.

The present application provides a VVN001-containing ophthalmic composition comprising an active material selected from a sodium salt represented by formula I and / or a free acid thereof, and ophthalmic excipients, to reduce the ocular inflammatory response by inhibiting a T cell-mediated inflammatory response through the active material. The concentration of the buffering agent in current invention is very low and the final buffer capacity of this ophthalmic composition is very close to the buffering capacity of the tear, which is tear-friendly and comfortable, and to increase the average residence time of the active material of the present application, as well as to increase the bioavailability of the active material represented by formula I according to the present application.

The present invention provides a method of treating ALK-negative / LTK-positive cancer in a subject, comprising administering to the subject a pharmaceutically-effective dose of a linear inhibitor of ALK. The invention is of particular utility in treating multiple myeloma, including proteasome inhibitor-resistant multiple myeloma.

The present invention provides an ophthalmic composition containing VVN001. The ophthalmic composition containing VVN001 contains an active substance and an ophthalmic excipient, and the active substance is selected from the sodium salt represented by Formula I and / or the free acid of Formula I. The present invention reduces the inflammatory reaction in the eye by inhibiting the inflammatory reaction mediated by T cells by the active substance. The present invention further selects a low concentration of pH buffer concentration to match the buffer capacity of the pH buffer concentration in tears, is gentle to tears, has a strong sense of comfort, increases the mean residence time of the active substance of the present invention, and improves the bioavailability of the active substance represented by Formula I of the present invention. 【Chemical 1】 JPEG2025516407000025.jpg70136

The present disclosure provides herein, inter alia, methods of treating patients diagnosed with amyotrophic lateral sclerosis (ALS).

This invention provides an antigen-binding protein that binds to proprotein converterase subtilisin kexin type 9 (PCSK9), as well as a method for using and producing the antigen-binding protein. [Solution] The present invention provides an isolated neutralizing antigen-binding protein that interacts with proprotein converterase subtilisin kexin type 9 (PCSK9), and which contains a specific amino acid sequence that binds to the PCSK9 protein and reduces the LDLR-reducing effect of PCSK9 on LDLR.

To provide a pharmaceutical composition useful for treating, alleviating, or inhibiting the progression of neurodegenerative diseases or conditions associated with tauopathy.SOLUTION: A pharmaceutical composition for reducing lipid peroxidation in a patient, comprising a compound of formula (I), or a salt thereof, wherein the concentration of the composition when administered to a patient is at least 20% of the liposomal lipid bilayer of the patient.SELECTED DRAWING: None

The present invention provides CDK2 inhibitors, methods for preparing the same, and pharmaceutical compositions, as well as the use of said compounds or pharmaceutical compositions in the preparation of medicaments for preventing or treating CDK2-mediated related diseases, including abnormal cell growth. [Formula 1] TIFF2025539116000135.tif28170

The invention relates to a steroidal compound as well as a preparation method and application thereof. Specifically, the invention provides a compound shown as a general formula (I), a stereoisomer or pharmaceutically acceptable salt of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and application of the compound as a GABAa receptor modulator to treatment of CNS-related diseases.

Disclosed herein are novel bifunctional compounds formed by combining an EGFR inhibitor moiety and an E3 ligase ligand moiety that function to recruit target proteins to E3 ubiquitin ligase for degradation, and methods for their preparation and use.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present invention relates to methods of treating endometriosis or preventing recurrence of endometriosis. In particular, the present invention relates to a method of treating endometriosis and relapse thereof, comprising administering to a woman suffering from endometriosis a pharmaceutical composition comprising an S-alkyl isothiourea derivative, in particular S-ethyl isothiourea diethyl phosphate. The methods and pharmaceutical compositions of the present invention can retain fertility and can be fertilized.

The present invention provides novel mitochondria-targeted Atovaquone compounds (Mito-ATO), a mitochondria-targeted derivative of Atovaquone, and methods of using such compounds. Methods of treating cancer using mito-ATO are also provided. Methods of enhancing an anti-tumor immune response by administering mito-ATO are further provided.

The present disclosure is related to STING agonists, pharmaceutical compositions thereof, and the use of the agonists and pharmaceutical compositions to induce a STING-mediated immune response and / or to treat diseases and disorders mediated by STING, such as cellular proliferative disorders, including, but not limited to, cancer.

The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereoisomer, solvate, hydrate, polymorph, or isotopic variant thereof, which can promote the binding of butyrophilin 3A1 / 2A1, and the definitions of each group in formula (I) are as detailed in the specification and claims. The present invention also relates to pharmaceutical compositions containing the compound of formula (I) and their use in clinical treatment. [C1] TIFF2026503047000176.tif29156

This invention discloses a (4-oxopent-1-ynyl)(diphenylcyclohexylphosphine) gold (I) and its application in the preparation of drugs for treating melanoma, belonging to the field of biomedicine. This invention provides a novel (4-oxopent-1-ynyl)(diphenylcyclohexylphosphine) gold (I) that effectively combats melanoma by inhibiting the proliferation and growth of melanoma cells, with low side effects. It can serve as a candidate drug for treating melanoma-related diseases caused by various factors, showing promising application prospects in the development of innovative drugs for melanoma treatment. It provides a new drug option for the treatment of melanoma and can alleviate the problems of relatively limited current treatment options and drug resistance.

The present invention relates to a drug for treating or preventing ALK fusion gene-positive cancer positive for FGFR1 expression and positive for FGF2 expression at baseline, the drug comprising a compound having ALK inhibitory activity and a FGFR inhibitor in combination, a combination agent, a pharmaceutical composition, a preparation, a treatment or prevention method, or a drug for suppressing acquisition of resistance, a method for selecting a patient, and the like.

The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of the discomforts of dermatological disorders (e.g., diseases) The treatment is for the dysesthesia (e.g., caused by irritation, itch, or pain) due to dermatitis, urticaria; scalp itch; vulvar itch; lichen sclerosus; cholestatic itch; psoriasis; sebhorrheic dermatitis; allergic conjunctivitis; blepharitis; and pruritus of the elderly. The applicant has found that topical delivery of DIPA compounds to the skin alleviates the dysesthesia of these conditions in human subjects. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in the treatment of the dysesthesia of these dermatological disorders.